Main Article Content

Abstract

Background: Extravasation of intravenous chemotherapeutic agents is one of the most devastating complications, which unacceptable condition neither to patient nor to medical services. Many healthcare providers realize that even one extravasation injury is too many since this injury is preventable. Published incidence rates of chemotherapy extravasation range from 0,01% to 6%, but in our institution, chemotherapy extravasation was not well recorded, so the incidence
rate is unclear and the number of injuries is underestimated.


Method: We observed chemotherapy extravasation occurrence during a 6 months period in our institution, from September 2013 until March 2014. We recorded the chemotherapy agents, patient’s clinical presentations, and extravasation management.


Result: During our observation, 1374 chemotherapies administered, and 10 cases of chemotherapy extravasation occur, particularly doxorubicine was the main chemotherapy agent. Almost all treated conservatively, only 10% handled with surgical management. Eventually, 20% of cases have implanted port placed.


Conclusion: Extravasation of cytotoxic agents is a serious problem, it causes tissue damage, prolongs the length of stay, increases hospital cost and psychological damage to cancer patients who under chemotherapy. It preventable but always underestimate by some clinicians, the use of central venous access device is one of the solutions to minimize the damage.

Keywords

extravasation vesicant agents central venous access device

Article Details

How to Cite
Kurniawati, I., & Adiputra, P. A. T. (2018). A PRELIMINARY STUDY ON THE EXTRAVASATION OF INTRAVENOUS CHEMOTHERAPY IN SANGLAH GENERAL HOSPITAL, BALI – INDONESIA. Neurologico Spinale Medico Chirurgico, 1(3), 72-75. Retrieved from https://nsmc.indoscholar.com/index.php/nsmc/article/view/22

References

  1. Una Cidon E, Contaldo A, Cocozza G. A Silent Chemotherapy Extravasation as the Unexpected Enemy: A Case Report. Webmed Central Oncology. 2011; 2(9). DOI: 10.9754/journal.wmc.2011.002261
  2. Langer SW, Sehested M, Jensen PB. Anthracycline Extravasation: A Comprehensive Review of Experimental and Clinical Treatments. Tumori. 2009; 95(3): 273-282. DOI: 10.1177/030089160909500301
  3. Ener RA, Meglathery SB, Styler M. Extravasation of Systemic Hemato-Oncological Therapies. Annals of Oncology. 2004; 15(6): 858-862. DOI: 10.1093/annonc/mdh214
  4. Schrijvers DL. Extravasation: A Dreaded Complication of Chemotherapy. Annals of Oncology. 2003; 14 (Suppl 3):iii26-iii30. DOI: 10.1093/annonc/mdg744
  5. Thakur JS, Chauhan CGS, Diwana VK, et al. Extravasational Side Effects of Cytotoxic Drugs: A Preventable Catastrophe. Indian J Plast Surg. 2008; 41(2):145-150. DOI: 10.4103/0970-0358.44923
  6. Mouridsen HT, Langer SW, Buter J, et al. Treatment of Anthracycline Extravasation with Savene (Dexrazoxane): Result from Two Prospective Clinical Multicentre Studies. Annals of Oncology. 2007; 18(3): 546-550. DOI:10.1093/annonc/mdl413
  7. Mitsuma A, Sawaki M, Shibata T, et al. Extravasation of Pegylated-Liposomal Doxorubicin: Favorable Outcome after Immediate Subcutaneous Administration of Corticosteroids. Nagoya J Med.Sci. 2012; 74(1-2): 189-192. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4831265/
  8. Schulmeister L. Vesicant Chemotherapy Extravasation Antidotes and Treatments. Clinical Journal of Oncology Nursing. 2008; 13(4):395-398. DOI: 10.1188/09. CJON.395-398
  9. Lancashire and South Cumbria Cancer Network. Policy for the Management of Extravasation Version 3.1. Chemotherapy Network Group, editor. NHS; 2011. Rev June 2013. Available from: https://studyres.com/download/8030784
  10. Fidalgo JA, Fabregat LG, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. Annals of Oncology. 2012; (Suppl 7) 23: vii67-vii73. DOI: 10.1093/annonc/mds294
  11. Gilleece C. Policy and Procedure Extravasation of Cytotoxic Chemotherapy. Royal United Hospital Bath NHS. Aug 2009. Rev Aug 2012.
  12. WOSCAN Cancer Nursing and Pharmacy Group. Chemotherapy Extravasation Guidelines. Sept 2009. Rev Sept 2012.
  13. Piko B, Laczo I, Szatmari K, et al. Overview of Extravasation Management and Possibilities for Risk Reduction Based on Literature Data. Journal of Nursing Education and Practice. 2013; 3(9): 93-105. DOI: 10.5430/jnep.v3n9p93
  14. Schulmeister L, Preventing and Managing Vesicant Chemotherapy Extravasations. The Journal of Supportive Oncology. 2010; 8(5): 212-215. DOI: 10.1016/j.suponc.2010.09.002
  15. Evans L, Galloway J, Hall K, et al. Extravasation Guidelines. North Trent Cancer Network V4. Apr 2011. Rev 2013.
  16. Ashwoth L. Anthracycline Extravasation: Reducing Risk and Improving Quality in the Community Setting. Oncology Issues. 2010; 20-25. DOI: 10.1080/10463356.2010.11883772
  17. North East Yorkshire and Humber Clinical Alliance (Cancer). Guidelines for the Management of Chemotherapy Extravasation in Adults Ver 1.5. 2011. Rev. 2014.
  18. Stoios N, Prevention of Extravasation in Intravenous Therapy: A Review of The Research Evidence. Nuritinga Electronic Journal of Nursing. 1999; 2:2-8. Available from: http://ecite.utas.edu.au/17872